Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially in pancreatic cancer, with stable disease maintained.
Viatris reports Q1 EPS in line with consensus at $0.67, with sales slightly missing expectations at $3.66 billion. Strong growth in Emerging Markets and Europe offset by challenges in North America. Guidance adjusted slightly downward for 2024.
SNDL Inc. reported on Thursday its financial and operational results for the first quarter ended March 31, 2024.The company reported a total net revenue of CA$197.7 million, up from CA$191 million in the prior year's period. Out of that sum cannabis retail revenue amounted to CA$71.3 million, while cannabis operations totaled CA$22.4 million.SNDL attributed the increase to the cannabis retail and cannabis operations segments, as the liquor retail segment reported flat net revenue.
Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 54.6%. Expecting operating profit of 225 billion yen in 2024.